Kidney Allograft Dysfunction Without Reversible Causes

Phase 4

Withdrawn

• Conditions: Kidney Graft Dysfunction
• Interventions: Drug: Cyclosporins/Tacrolimus; Drug: Sirolimus

• Registration Number: NCT01492894
• Lead Sponsor: University of Minnesota

Brief Summary

The purpose of this study is to learn the best way to prolong kidney life in patients exposed to calcineurin inhibitors, who already have evidence of damage possibly caused by the calcineurin inhibitor on kidney biopsy.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2010-08-09
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Study First Submitted QC: 2011-12-13
• Study First Posted: 2011-12-15
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-08
• Last Update Posted: 2016-12-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Serum creatinine increased greater than or equal to 25% over baseline with no acute or reversible cause clinically evident.

   Although eGFR is arguably better for estimating kidney allograft function than serum creatinine, pragmatics dictate the use of a change in serum creatinine in the initial selection of patients. These criteria are currently used by transplant coordinators for selection of patients for the kidney biopsy as a part of large on-going study at our center.

2. Adequate (greater than or equal to 8 glomeruli) biopsy showing Chronic allograft injury reported as mild/moderate CAN or CNI toxicity based on the previously used Banff 97 classification and no potentially reversible causes of graft dysfunction, e.g. acute rejection or treatable recurrent disease. Patients with histological evidence of mild recurrent disease that does not appear to be severe enough to explain the deterioration in function, e.g. IgA on immunofluorescence, or changes consistent with early diabetic nephropathy, will not be excluded.

3. Receiving CsA (trough level concentration 75-125 ng/mL) or Tacrolimus(trough level concentration 6-12 ng/mL) plus MMF (or AZA) with (or without) prednisone.

4. Able to give informed consent.

Exclusion Criteria

1. Urine total protein excretion >500 mg/g creatinine.
2. eGFR (estimated by MDRD) <40 mL/min/1.73 m2
3. Triglycerides >400 mg/dL or total cholesterol >300 mg/dL
4. Allergy to macrolide antibiotic or rapamycin
5. Women of child-bearing potential not using effective contraception
6. Treated for acute rejection within the past 2 months
7. <12 months after transplantation
8. Potentially treatable cause(s) of allograft dysfunction, including acute rejection, dehydration, and congestive heart failure.
9. Recurrent or de novo kidney disease that is histologically severe enough to be causing graft dysfunction
10. Polyoma virus (BK) nephropathy, or serum positive for BK by polymerase chain reaction
11. A second, functioning organ transplant.
12. Receiving sirolimus.
13. Patients with any past or present malignancy (other than non-melanoma skin cancer)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
50% decrease in calcineurin inhibitor	Cyclosporins/Tacrolimus	-
Rapamune	Sirolimus	-

Primary Outcome Measures

Name	Time	Method
Kidney function will be determined by the rate of change in glomerular filtration rate (GFR), estimated by serum creatinine (eGFR).	Once a week for 3 month then monthly until trial ends

Trial Locations

Locations (1)

University of Minnesota Departments of Medicine and Surgery; 🇺🇸 Minneapolis, Minnesota, United States